Company
Headquarters: North Sydney, NSW, Australia
CEO: Mr. Nigel Lange
A$17.8 Million
AUD as of Jan. 1, 2024
US$12.1 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $192.67 B |
| Stryker Corporation | $113.24 B |
| Medtronic | $111.60 B |
| Boston Scientific Corporation | $85.22 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and bile duct cancer in Australia. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
OncoSil Medical Limited has the following listings and related stock indices.
Stock: ASX: OSL wb_incandescent